Pilot report: objective quantification of trabecular meshwork pigmentation using densitometry and the NIDEK GS-1 gonioscope in glaucoma patients.

Autor:	Laroche D; Department of Ophthalmology, New York Eye and Ear Infirmary, Icahn School of Medicine of Mount Sinai, New York, NY, United States.; Department of Ophthalmology, Advanced Eyecare of New York, New York, NY, United States., Brown A; Department of Ophthalmology, New York Eye and Ear Infirmary, Icahn School of Medicine of Mount Sinai, New York, NY, United States., Sinon J; Department of Ophthalmology, Downstate Medical Center, New York, NY, United States., Martin A; Department of Ophthalmology, Northwell Health, New York, NY, United States., Ng C; Department of Ophthalmology, Advanced Eyecare of New York, New York, NY, United States., Sakkari S; Department of Ophthalmology, Advanced Eyecare of New York, New York, NY, United States.
Jazyk:	angličtina
Zdroj:	Frontiers in ophthalmology [Front Ophthalmol (Lausanne)] 2024 Jan 23; Vol. 3, pp. 1322178. Date of Electronic Publication: 2024 Jan 23 (Print Publication: 2023).
DOI:	10.3389/fopht.2023.1322178
Abstrakt:	In this case series, we present a methodology for a proof of principle for the development of a unique biomarker for pigmentary glaucoma to detect progression before nerve fiber layer loss. Out of the five patients in this case series, one was excluded because of an outlier due to pseudoexfoliation syndrome with excessively dense pigmentation of the trabecular meshwork. The remaining patients displayed a decreased visual field loss with increased superior to inferior trabecular meshwork ratios. This methodology, though limited due to small sample size, shows that in a limited number of patients, visual field loss is positively correlated with increased superior to inferior trabecular meshwork ratios. The next steps would be to look at patients without glaucoma and patients with pigmentary glaucoma, along with complete inter-eye comparisons for patients with unilateral exfoliation syndrome to act as controls. To our knowledge, this is a novel methodology, and if the pattern holds, it can act as proof of principle for the development of a novel early biomarker for pigmentary glaucoma to improve early intervention and delay vision loss. Competing Interests: DL is a consultant for Sight Sciences, Alcon, Nidek. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2024 Laroche, Brown, Sinon, Martin, Ng and Sakkari.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu